Abstract
X-ray computed tomography (CT), an efficient non-invasive clinical technique, usually provides highresolution 3D structure details of tissues in early disease diagnosis. Here, we report a high-performance CT imaging platform based on a monodispersed Yb-based nanoparticulate contrast agent. The well-prepared nanoprobes presented excellent in vitro and in vivo performances in the CT imaging, very low cytotoxicity and no detectable tissue damage in one month. More significantly, compared with routinely used Iobitridol in clinic, our Yb-based CT contrast agents provided much more enhanced contrast at a clinical 120 kVp voltage. Additionally, these nanoparticulate contrast agent could be excreted mainly via feces and urine, indicating the total elimination from the animal bodies and more potential for further biomedical applications.
Keywords: Yb-based nanoparticles, imaging agent, biocompatibility, large-scale synthesis, biomedicine.
Current Topics in Medicinal Chemistry
Title:Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Volume: 13 Issue: 4
Author(s): Jianhua Liu, Rui Xin, Zhiman Li, Reza Golamaully, Yan Zhang, Jishen Zhang, Qinghai Yuan and Xiaodong Liu
Affiliation:
Keywords: Yb-based nanoparticles, imaging agent, biocompatibility, large-scale synthesis, biomedicine.
Abstract: X-ray computed tomography (CT), an efficient non-invasive clinical technique, usually provides highresolution 3D structure details of tissues in early disease diagnosis. Here, we report a high-performance CT imaging platform based on a monodispersed Yb-based nanoparticulate contrast agent. The well-prepared nanoprobes presented excellent in vitro and in vivo performances in the CT imaging, very low cytotoxicity and no detectable tissue damage in one month. More significantly, compared with routinely used Iobitridol in clinic, our Yb-based CT contrast agents provided much more enhanced contrast at a clinical 120 kVp voltage. Additionally, these nanoparticulate contrast agent could be excreted mainly via feces and urine, indicating the total elimination from the animal bodies and more potential for further biomedical applications.
Export Options
About this article
Cite this article as:
Liu Jianhua, Xin Rui, Li Zhiman, Golamaully Reza, Zhang Yan, Zhang Jishen, Yuan Qinghai and Liu Xiaodong, Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging, Current Topics in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1568026611313040011
DOI https://dx.doi.org/10.2174/1568026611313040011 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Prospective Clinical Role for Anticancer Garlic Organosulfur Compounds (Guest Editor: Hassan T. Hassan)]
Anti-Cancer Agents in Medicinal Chemistry Collaborative and Defensive Fibroblasts in Tumor Progression and Therapy Resistance
Current Medicinal Chemistry Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry SUBJECT INDEX TO VOLUME 4 Current Organic Chemistry
Current Organic Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Hypocholesterolemia
Current Vascular Pharmacology Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Cancer Nanotechnology: Recent Trends and Developments in Strategies for Targeting Cancer Cells to Improve Cancer Imaging and Treatment
Current Drug Metabolism VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy
Current Molecular Medicine Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells
Current Drug Discovery Technologies Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders Quantitative Analysis of Microbial Metabolism in the Human Large Intestine
Current Nutrition & Food Science Multidrug Resistance in Cancer Chemotherapy and Xenobiotic Protection Mediated by the Half ATP-Binding Cassette Transporter ABCG2
Current Medicinal Chemistry - Anti-Cancer Agents Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Modeling Anti-Allergic Natural Compounds by Molecular Topology
Combinatorial Chemistry & High Throughput Screening Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Controlling Protein Transport by Small Molecules
Current Drug Targets The Effect of Natural Soluble Polysaccharides on the Type 2 Diabetes through Modulating Gut Microbiota: A Review
Current Medicinal Chemistry Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry